Category Archives: Iowa Stem Cells

The Blood and Marrow Transplant Program at University of Iowa Hospitals and Clinics in Iowa City, Iowa has been performing stem cell transplants since 1980. The program has earned reaccreditation from the Foundation for the Accreditation of Cellular Therapy (FACT), putting Iowa's BMT program on a select list of institutions that meet the most rigorous standards in every aspect of stem cell therapy, including clinical care, donor management, cell collection, processing, storage, transportation, administration, and cell release.

A bone marrow transplant is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells.

There are several alternative names for a blood and marrow transplant, including:

Our experienced team has provided over 3300 stem cell transplantsadult,pediatric, allogeneic and autologoussince 1980. Learn more about why the UI Blood and Marrow Transplant Program is your best choice for care.

There are three kinds of bone marrow transplants:

The term auto means self. Stem cells are removed from you before you receive high-dose chemotherapy or radiation treatment. The stem cells are stored in a freezer (cryopreservation). After high-dose chemotherapy or radiation treatments, your stems cells are put back in your body to make (regenerate) normal blood cells. This is called a rescue transplant.

The term allo means other. Stem cells are removed from another person, called a donor. Most times, the donor's genes must at least partly match your genes. Special blood tests are done to see if a donor is a good match for you. A brother or sister is most likely to be a good match. Sometimes parents, children, and other relatives are good matches. Donors who are not related to you may be found through national bone marrow registries.

This is a type of allogeneic transplant. Stem cells are removed from a newborn baby's umbilical cord right after birth. The stem cells are frozen and stored until they are needed for a transplant. Umbilical cord blood cells are very immature so there is less of a need for matching. But blood counts take longer to recover.

Before the transplant, chemotherapy, radiation, or both may be given. This may be done in two ways:

High-dose chemotherapy, radiation, or both are given to kill any cancer cells. This also kills all healthy bone marrow that remains, and allows new stem cells to grow in the bone marrow.

Patients receive lower doses of chemotherapy and radiation before a transplant. This allows older patients, and those with other health problems to have a transplant.

A stem cell transplant is done after chemotherapy and radiation is complete. The stem cells are delivered into your bloodstream usually through a tube called a central venous catheter. The process is similar to getting a blood transfusion. The stem cells travel through the blood into the bone marrow. Most times, no surgery is needed.

Adult solid tumors

Pediatric solid tumors

Most patients receiving a stem cell transplant are in their fifties and sixties. Sometimes, they are a little older. Transplantation is a very intensive therapy, and we need to have some reassurance that patients have a good chance of surviving and will not succumb to such intensive therapy. We try to maximize success and minimize the risk of patients actually having their life shortened by a stem cell transplant.

To assess the fitness of a patient to receive a transplant, we test:

In addition, we will ensure that there is no active infection by doing blood work and imaging tests such as CT chest, CT sinuses and/or PET-CT scan. These tests are arranged prior to the first clinic visit so that the results can be reviewed and decisions can be made about treatment options during the visit with the specialist.

The transplant process is outlined in detail in our Allogeneic and Autologous Guidebooks and instructional videos.

Original post:
Blood and Marrow Transplant Program | University of Iowa ...

Select a Problem Area

If you have pain, we're here to help. Regenexx Procedures are patented stem cell and blood platelet procedures that are used to treat a wide range of joint and spine conditions.

Click a problem area to discover what Regenexx can do for you.

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from shoulder pain due to arthritis, rotator cuff and shoulder labrum tears, overuse injuries, and other degenerative conditions. Regenexx is also a viable alternative for those considering shoulder replacement surgery.

View Details About Shoulder Treatments

Commonly Treated Conditions:

Shoulder Procedure Video

Regenexx Procedures are advanced stem cell and blood platelet procedures for foot and ankle conditions. Before you consider ankle surgery, fusion or replacement, consider the worlds leading stem cell and prp injection treatments.

View Details About Foot & Ankle Treatments

Commonly Treated Conditions:

Ankle Procedure Video

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from pain or reduced range of motion due to basal joint / cmc arthritis, hand arthritis, or other injuries & conditions in the hand.

View Details About Hand & Wrist Treatments

Commonly Treated Conditions:

The Regenexx family of non-surgical stem cell and blood platelet procedures offer next-generation injection treatments for those who are suffering from knee pain or may be facing knee surgery or knee replacement due to common injuries, arthritis, overuse and other conditions.

View Details About Knee Treatments

Commonly Treated Conditions:

ACL Procedure VideoIn-Depth with Dr. John Schultz ACL Procedure Video

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from pain, inflammation or reduced range of motion due tocommon elbow injuries, arthritis and overuse conditions.

View Details About Elbow Treatments

Commonly Treated Conditions:

The Regenexx family of hip surgery alternatives are breakthrough, non-surgical stem-cell treatments for people suffering from hip pain due to common injuries, hip arthritis & other degenerative problems related to the hip joint.

View Details About Hip Treatments

Commonly Treated Conditions:

Hip Labrum Procedure Video Hip Avascular Necrosis Procedure Video

Regenexx has many non-surgical platelet and stem cell based procedures developed to help patients avoid spine surgery and high dose epidural steroid side effects. These procedures utilize the patients own natural growth factors or stem cells to treat bulging or herniated discs, degenerative conditions in the spine, and other back and neck conditions that cause pain.

View Details About Spine Treatments

Commonly Treated Conditions:

Intradiscal Procedure Video

Regenexx has many non-surgical platelet and stem cell based procedures developed to help patients avoid spine surgery and high dose epidural steroid side effects. These procedures utilize the patients own natural growth factors or stem cells to treat bulging or herniated discs, degenerative conditions in the spine, and other back and neck conditions that cause pain.

View Details About Spine Treatments

Commonly Treated Conditions:

Cervical Spine Video

See original here:
Regenexx Des Moines | Iowa's Regenexx Provider

The Joint Preservation Institute of Iowa is now offering stem cell therapy in Des Moines.

Dr. Goding is one of the firstorthopaedic surgeons in the nation to offer this treatment. He uses autologous stem cell therapy and the regenerative power of mesenchymal stem cells to give patients another treatment option for dealing with orthopaedic conditions, such as osteoarthritis and other degenerative joint conditions.

You may benefit from orthopaedic stem cell therapy if you have:

Mesenchymal stem cells (MSCs) are adult stem cells found in bone marrow. The Joint Preservation Institute of Iowa performs autologous stem cell therapy, which means that the stem cells used in your treatment are taken from your own body, not from a donor. Using your own stem cells for the procedure helps reduce your risk of infection and eliminate the possibility of immune rejection.

In an autologous stem cell procedure, Dr. Goding will draw a sample of bone marrow from the iliac crest of your hip. The sample is filtered and concentrated in a sterile environment, then injected into the area of your body needing help to heal. This procedure is done on an outpatient basis while under sedation and leaves no scarring.

The idea behind orthopaedic stem cell therapy is that the injection of these concentrated regenerative cells at an area of your body experiencing degeneration will kick-start your bodys ability to heal itself. These injections can be given as an independent treatment or in conjunction with a surgical procedure.

Most cells in the human body have an assigned purpose. They are liver cells, fat cells, bone cells and so on. These cells can replicate more of their own kind, but they cannot create another type of cell.

Stem cells are the primitive cells from which all other cells developed. They are undifferentiated cells with the ability not only to self-replicate, but also to become different types of human cells. There are several types of stem cells, but the kind used in orthopaedic stem cell therapy are called mesenchymal stem cells (MSCs).

Bone Marrow Concentrate

Dr. Goding uses the BioCUE system from Zimmer Biomet. This system produces 77.5% recovery of nucleated cells.

Higher available cell numbers have correlated with improved results.

Autologous Protein Solution (APS)

APS is the newest treatment in the field of injectable orthobiologics. This procedure is essentially a further processing of platelet rich protein (PRP).

The tremendous advantage of APS is that it is derived from the blood instead of bone marrow. It is less painful, has less potential for injury, is less costly and it provides similar results.

After APS is derived from the blood, it is processed into PRP and then processed into APC. Using APC prevents macrophage cells from destroying healthy cartilage cells and has a profound anti-inflammatory effect in the joint. It also promotes growth and health of existing cartilage cells.

A recent study has shown up to 70 % pain reduction at 6 months in patients undergoing this procedure.

Dr. Goding uses the nSTRIDE system for APS treatments. An MSC has strong potential for tissue repair because it can:

In medical research, tissues such as muscles, cartilage, tendons and ligaments have shown some capacity for self repair. As a result, tissue engineering and the use of MSCs and/or bio-active molecules, such as growth factors, are being tested and studied to determine the role they can play in tissue regeneration and repair.

Articular Cartilage Damage to the articular cartilage following an injury has poor potential for repair and can lead to arthritic changes many years later. Recent studies have shown favorable outcomes and better knee scores at two-year follow ups for bone marrow derived MSCs that those of current techniques of microfracture and autologous chondrocyte implantation.

Bone Trauma and some pathological conditions can lead to extensive bone loss, which requires transplantation of bone and other bone substitutes to restore structural integrity. A large number of studies have shown great potential for mesenchymal cells to repair critically sized bone defects, producing better bone growth and more robust bone formation than controlled groups.

Tendons and Ligaments Injuries to tendons and ligaments heal by forming new tissues of inferior quality. Autografts, allografts and resorbable materials have been used to repair defects in tendons and ligaments, but these carry risks, such as donor site morbidity, scar formation and tissue rejection. A number of studies on the use of MSCs to improve the repair of tendons and tendon defects have been carried out with favorable results when measured in histology and tissue strength. The use of mesenchymal cells with tissue allografts enhances the graft and improves the biomechanical properties compared to control studies.

Meniscus Most tears of the meniscus occur in avascular zones with little or no potential for repair. Standard biological healing processes produce limited results and meniscectomy (removal of all or part of the torn meniscus) has been shown to have a strong association with subsequent development of osteoarthritis. Recently, studies have shown that self-paced therapy, including MSCs, demonstrates biological healing and adherence of meniscal tears in avascular zones.

Initial Visit An initial consultation with Dr. Goding will be required to find out if you are a candidate for stem cell therapy. In some cases, an MRI may be recommended to confirm your diagnosis and rule out any underlying conditions that could cause complications. If you are determined to be a candidate for stem cell therapy, your procedure will be scheduled for another day. This initial consultation is usually covered by your insurance plan.

Preparation For two weeks prior to your procedure, do not take aspirin or anti-inflammatory medications (NSAIDS).

Procedure Stand-alone stem cell therapy is done as an outpatient procedure, so most patients will leave the clinic and resume low impact activities the same day. Some patients have reported mild pain for 48-72 hours after their procedure, but this can often be attributed to the absence of their routine anti-inflammatory medications. After this time period, most patients will experience a gradual decrease in pain and some may begin to notice increased function.

Post-procedure To give your procedure the best chance to provide lasting results, our physicians recommend the following post-procedure restrictions:

Please note: If you are having a stem cell therapy procedure in conjunction with another surgical procedure, your recommendations may change. Consult with your physician on the guidelines and restrictions for your specific case.

No. Because mesenchymal stem cell (MSC) injections are considered investigational for orthopaedic applications, most insurance companies will not cover the cost. Please contact our office to discuss cash payment options.

Go here to read the rest:
Stem Cells - Joint Preservation Institute of Iowa

NASA astronaut Peggy Whitson returned Earth on Saturday, marking the end of her record-breaking time in space. Whitson spent several months working on the International Space Station, the $100-billion orbiting laboratory located about 250 miles above Earth.

The astronaut made the trip back home with NASA astronaut Jack Fischer and Roscosmos cosmonaut Fyodor Yurchikhin. The trio safely landed the Soyuz MS-04 capsule on Earth at 9:21 EDT Saturday southeast of Dzhezkazgan in Kazakhstan.

Whitson and Fischer contributed to hundreds of experiments in biology, physical science, biotechnology, and Earth science during their stay at the orbiting outpost. Whitson, 57, now holds the U.S. record for most time in space, as she totals 665 days in orbit.

This marked Whitsons third mission to the ISS. Her 288-day mission to the space outpost which spanned 122.2 million miles and 4,623 orbits of our planetbegan in November last year. She performed four spacewalks, bringing her overall total to ten. The biochemist has repeatedly shared her enthusiasm and love for her job.

I feel great, said Whitson during an in-flight interview on Monday, according to Reuters. I love working up here. Its one of the most gratifying jobs Ive ever had.

Whitson spent most of her time in the mission working on numerous scientific experiments. Fischer and Whitson supported research in a study on how astronauts eyes can change due to prolonged exposure to a microgravity environment. The duo also conducted a new lung tissue study that analyzes how stem cells work in the microgravity environment of the space station, which could help for future research on stem cells.

NASA says Fischer and Whitson also worked on a study on antibody investigation, to increase the effectiveness of chemotherapy drugs for cancer treatment, as well as a study of plant physiology and growth in space using an advanced plant habitat.

The astronauts, who also welcomed cargo spacecraft delivering tons of supplies, food, and research experiments, helped to attach the Cosmic Ray Energetics and Mass Investigation (ISS CREAM) on the exterior of the ISS in August, which is currently observing cosmic rays from across the galaxy.

Whitson also set a record for the most time spent spacewalking by a woman. She was due to return to Earth three months ago with the two crewmates who traveled with her in November. However, she stayed longer to fill a vacancy after Russia announced it would reduce its station staff from three to two cosmonauts.

During another in-flight interview, Whitson said she looked forward to reuniting with her loved ones.

Im looking forward to seeing friends and family, she said, according to Reuters. But the thing Ive been thinking about the most, kind of been fantasizing about a little bit, are foods that I want to make, vegetables that I want to saut, things that Ive missed up here.

Back in April, she broke the 534-day U.S. record for cumulative time in space. She is now part of a space hall of fame that includes seven Russian cosmonauts in the first spots. The world record-holder for cumulative time in space is Russian cosmonaut Gennady Padalka, who spent a total 878 days in orbit.

Whitson grew up in Iowa and says she was drawn to the National Aeronautics and Space Administration after the U.S. Apollo program that landed men on the moon. When women were able to join the space agency, she also applied. Whitson became an astronaut in 1996 and was the first woman to command the ISS and the first woman and first non-pilot to serve as chief of the NASA Astronauts Corps.

Yurchikhin, who came back with the American astronauts, also broke his record, as he has spent a total of 673 days in space, putting him seventh (one spot higher than Whitson) on the all-time space endurance list.

The Russian cosmonaut will head to Russias cosmonaut center in Moscow, and Fischer and Whitson will go to NASAs Johnson Space Center in Houston.Because hurricane Harvey caused severe damages all across Houston, NASA was forced to close the center temporarily and to come up with a contingency plan for getting Fischer and Whitson home.

NASA teamed up with the European Space Agency and sent the astronauts to the ESA center in Cologne, Germany. There, the NASA Gulfstream jet is scheduled to pick them up and carry them back to Houston on Sunday night. Whitson recently said NASA has been working non-stop after Harvey.

Our home is fine, but so many friends and co-workers have been impacted [by the storm], Whitson said in an interview with NASA, according to Space.com. For example, in order to keep mission control running, the team (three shifts of a skeleton support crew) were sleeping on cots in the backup mission control rooms. Their sacrifices for the station and keeping things running up here are amazing.

Source: Reuters

Link:
US record holder for most time in space Peggy Whitson returns to Earth after 288-day mission - Pulse Headlines

The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.

Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.

"There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt assurances to patients based on unproven and, in some cases, dangerously dubious products," FDA Commissioner Scott Gottlieb said in a statement Monday.

The FDA has taken action against clinics in California and Florida.

The agency sent a warning letter to the US Stem Cell Clinic of Sunrise, Fla., and its chief scientific officer, Kristin Comella, for "marketing stem cell products without FDA approval and significant deviations from current good manufacturing practice requirements."

The clinic is one of many around the country that claim to use stem cells derived from a person's own fat to treat a variety of conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lung and heart diseases, the FDA says.

The Florida clinic had been previously linked to several cases of blindness caused by attempts to use fat stem cells to treat macular degeneration.

The FDA also said it has taken "decisive action" to "prevent the use of a potentially dangerous and unproven treatment" offered by StemImmune Inc. of San Diego, Calif., and administered to patients at California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif.

As part of that action, the U.S. Marshals Service seized five vials of live vaccinia virus vaccine that is supposed to be reserved for people at high risk for smallpox but was being used as part of a stem-cell treatment for cancer, according to the FDA. "The unproven and potentially dangerous treatment was being injected intravenously and directly into patients' tumors," according to an FDA statement.

Smallpox essentially has been eradicated from the planet, but samples are kept in reserve in the U.S. and Russia, and vaccines are kept on hand as a result.

But Elliot Lander, medical director of the California Stem Cell Treatment Centers, denounced the FDA's actions in an interview with Shots.

"I think it's egregious," Lander says. "I think they made a mistake. I'm really baffled by this."

While his clinics do charge some patients for treatments that use stem cells derived from fat, Lander says, none of the cancer patients were charged and the treatments were administered as part of a carefully designed research study.

"Nobody was charged a single penny," Lander says. "We're just trying to move the field forward."

In a written statement, U.S. Stem Cell also defended its activities.

"The safety and health of our patients are our number one priority and the strict standards that we have in place follow the laws of the Food and Drug Administration," according to the statement.

"We have helped thousands of patients harness their own healing potential," the statement says. "It would be a mistake to limit these therapies from patients who need them when we are adhering to top industry standards."

But stem-cell researchers praised the FDA's actions.

"This is spectacular," says George Daley, dean of the Harvard Medical School and a leading stem-cell researcher. "This is the right thing to do."

Daley praised the FDA's promise to provide clear guidance soon for vetting legitimate stem-cell therapies while cracking down on "snake-oil salesmen" marketing unproven treatments.

Stem-cell research is "a major revolution in medicine. It's bound to ultimately deliver cures," Daley says. "But it's so early in the field," he adds. "Unfortunately, there are unscrupulous practitioners and clinics that are marketing therapies to patients, often at great expense, that haven't been proven to work and may be unsafe."

Others agreed.

"I see this is a major, positive step by the FDA," says Paul Knoepfler, a professor of cell biology at the University of of California, Davis, who has documented the proliferation of stem-cell clinics.

"I'm hoping that this signals a historic shift by the FDA to tackle the big problem of stem-cell clinics selling unapproved and sometimes dangerous stem cell "treatments" that may not be real treatments," Knoepfler says.

Read more from the original source:
FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Iowa Public Radio

By RENEE WEBB rwebb@catholicglobe.org

As the use of stem cell research and therapy continues to expand, one medical research institute located in Iowa strives to uphold Catholic teachings in bioethics.

The John Paul II Medical Research Institute (JP2MRI), a non-profit of Iowa City, was founded by Dr. Alan Moy in 2007 to address a shortcoming when it came to pro-life values being upheld concerning a variety of medical practices and issues. The doctor also is co-founder and CEO of Cellular Engineering Technologies (CET), a for-profit biotechnology company that manufactures commercial adult stem cells and other biotechnology products.

He explained that JP2MRI was founded a year after starting CET to advance the application of adult stem technology to clinical applications in the area of neurodegenerative disease, rare disease, cancer and chronic diseases of unmet needs or in underperformed diseased areas. His concern was that the United States was falling behind other countries in the area of adult stem cell research.

Recently, through collaborative research by JP2MRI and CET, a new method for creating safer induced pluripotent stem cells, or iPSC, for clinical use was discovered.

We started work in traditional adult stem cells over a decade ago, Moy explained. The controversy was that among the secular scientific community, adult stem cells were viewed as inferior to embryonic stem cells because they could not convert or differentiate into the variety of cells that embryonic stem cells could.

When iPSC technology was discovered by a Japanese Nobel laureate scientist about 10 years ago, it was an ethical alternative to embryonic stem cells. iPSC are noncontroversial adult stem cells that are genetically reprogrammed into embryonic-like stem cells without using human embryos.

But that technology had inherent safety issues just like embryonic stem cells. Most embryonic stem cells and iPS cells have the risk of causing tumors because of their genetic instability, Moy said. What we worked on was trying to reduce the tumor risk.

Building on the original iPSC technology, JP2MRI and CET developed a method by using a variety of chemicals to replace known cancer-causing genes in the process.

Now we have an iPS technology that is safer, said Moy, who noted an added benefit is potential reduced cost in drug development.

Potential applications

He spoke about practical applications of this technology such as expanding the use of stored cord blood stem cells for future medical treatment if a disease develops in the child.

We have a means where we can take the cord blood and make an iPS cell which can have lifelong utility and diversity, Moy added.

For those who do not have stored cord blood, he said all is not lost as blood can be drawn and stored for people to create their own iPS cell for future use.

This technology can also provide a viable alternative to embryonic stem cells and aborted fetal tissue that are currently used by the pharmaceutical industry, noted Moy, to produce vaccines, gene therapy, cell therapy and protein therapeutics.

Right now with protein manufacturing, half of it is done using animal cells to produce human proteins, he explained. The problem is some of the human proteins that are produced have some minor animal characteristics and they are not entirely human so there is a push to produce purely human proteins out of human cells. Unfortunately, the vast majority of human cell lines used in protein manufacturing or in vaccine development are derived from aborted fetal tissue.

Moy anticipates there will increasingly be a movement to shift toward human cell manufacturing, and if we dont come up with non-controversial human cells, we are going to have a lot of controversial human protein therapeutics, gene therapies and vaccines that will be distributed at hospitals that must be administered by doctors.

Morals and ethics

This can create moral and ethical problems. Catholic hospitals and/or Catholic doctors will be forced to decide if they will use that type of product made with illicit cells.

We have to have alternative products that are equal or better than the products that are currently out there, said Moy.

The Catholic Church, as well as the average person, may not always be aware of the unethical nature of many of these products. Moy said he has been trying to communicate areas of concern to the Catholic community for years.

The evolution of biotechnology over decades has become secularized and the power is in the secularists, he said. Advancement of illicit-cell treatment and therapy is a serious potential threat to the Catholic health care system including Catholic hospitals and Catholics who are healthcare providers.

Moy feels strongly about Catholics and the church being pro-active in the bioethics arena.

The only way in which we can influence the biotechnology field is through innovation, he said. Through innovation, if you produce something they want that has technical advantage, then one can influence the direction of biotechnology. Pro-life individuals need to move from a passive bystander to an activist role.

That is part of the reason he founded the JP2MRI, which is grounded in a pro-life bioethics that respects the dignity of every human life. While more than 300 non-profit institutes and organizations engage in and support human embryonic stem cell research, JP2MRI seeks to find cures and therapies exclusively using a variety of adult stem cells and specifically the iPSC, which are derived from adult cells.

Moy said they are not only looking for ways to produce a variety of products using the safer iPS cells, but plan to license them so other scientists, companies and industries can take advantage of these cells to pursue more ethical biotechnology.

Read the original post:
Stem cells: JP2MRI, CET discover safer, more ethical biotechnology - Sioux City Catholic Globe

Progressive Rehabilition Medicine is an Iowa provider ofMesenchymal stem cell (MSC) therapy. We utilizea new medical technology that enables us to extract the stem cells from the patients own body fat (adipose). Adipose tissue contains a very high proportion of stem cells about 500 times more stem cells than are found in bone marrow.

Adipose tissue is also much easier to extract than bone marrow. Using a quick mini-liposuction technique, we are able to extract the fat cells, usually from the abdominal region. The extraction only takes about 20 minutes and is performed under local anesthesia.

Once the extraction is completed, the stem cells and growth factors are separated from the fat the same day right at our medical facility while complying with FDA Current Good Manufacturing Practice ("CGMP") requirements..

After the stem cells are extracted, the cells are then delivered back into the body via a minimally invasive precision guided injection. The entire process takes less than 2.5 hours to complete in most cases.

We also provide specialized stem cell rehab to build strength and recondition the weakened joint in order to address all the factors that contribute to the injury and lack of proper function.

PRESS RELEASE 10/29/2015

Learn about Dr. Sunny Kim's treatment of chronic knee pain using a highly specialized, minimally invasive, non-surgical, druglessprocedure.

The treatment harnesses the bodys own natural, recuperative healing cells.

Download OurPress Release (PDF)

We are happy to discuss Mesenchymal Stem Cell (MSC) Therapy or any other option that may work for you.Please call our office in Cedar Rapids Iowa at(319) 393-1320to schedule a consultation.

Click to downloadany article below for more information:

Learn more atwww.usstemcellclinic.com

See the article here:
Mesenchymal Stem Cell Therapy - Cedar Rapids, Iowa City ...

Each year it seems that patients from Des Moines and all over the world, are more at risk than ever for life threatening and chronic illness like COPD, Arthritis, Diabetes and cardiovascular diseases. It seems that traditional medicine has had a difficult time keeping up.

Des Moines is definitely part for Stem Cells Trend. Researchers from University of Iowa explained that they took skin stem cells from adult humans and retrained them to act as if they were pancreas cells. The pancreas is the organ whose failure causes diabetes, a dangerous condition that leaves the body unable to process sugar. The American Diabetes Associations top national expert called the Iowa research a cutting-edge approach.

In spite of the billionaire investment in stem cells investigation in Des Moines and the uncountable benefits of stem cells therapies; United States is still in the clinical trial phase, therapies have not been legally approved yet.

Whether you live in Clive, Grimes, Waukee, Johnston, Sioux Center, North Liberty. Westwood, Linden Heights, Waterbury, Salisbury Oaks, Greenwood or Ingersoll Park, now you can access stem cells treatment in Costa Rica.

The Stem Cells Transplant Institute of Costa Rica specializes in the legal treatment of Critical limb isquemia, Erectile Dysfunction, Cardiovascular Disease, Knee Injury, Chronic Obstructive pulmonary disease, Multiple Sclerosis, Lupus, Osteoarthritis, Rheumatoid Arthritis, Alzheimer, Parkinson, Myocardial infarction, Diabetes and Neuropathy.

Stem Cells Transplant Institute in Costa Rica, provides cutting-edge stem cells procedures that stimulate and support the bodys natural recovery mechanisms. State-of-the-art injection and intravenous therapies can eliminate the need of surgeries, and provide alternative therapies to our patients from Des Moines who struggles with many degenerative diseases.Apply Now

Original post:
Des Moines, Iowa Stem Cell Transplants, Clive, Grimes ...

Application

On March 9, 2009, President Barack Obama issued an Executive Order 13505: Removing Barriers to Responsible Scientific Research Involving Human Stem Cells. The National Institutes of Health Guidelines for Human Stem Cell Research (Guidelines) implement this Executive Order as it pertains to extramural NIH-funded stem cell research. The Guidelines establish policy and procedures under which the NIH will fund research involving human embryonic stem cells (hESCs) and certain uses of human induced pluripotent stem cells (iPSCs) and work to ensure such research is ethically responsible, scientifically worthy and conducted in accordance with applicable law.

The University of Iowa is responsible for ensuring that all stem cell research conducted at or sponsored by the University complies with theGuidelines. Compliance authority on campus is placed with the Human Pluripotent Stem Cell Committee (hPSCC). The hPSCC reviews stem cell research and approves those projects in conformity with the Guidelines and in accordance with the general principles expressed in the Guidelines for Human Embryonic Stem Cell Research (National Academies of Science, 2005) and its subsequent amendments. The hPSCC is appointed by and advises the Assistant Vice President for Research Compliance.

Researchers at the University of Iowa must be in compliance with the Guidelines, irrespective of the source of funding.

The eligibility of hESCs for research purposes is governed by the NIH. Researchers may use hESCs that are posted on the NIH Registry or they may establish eligibility for NIH Funding by submitting a compliance of assurance with Section II (A) of the Guidelines. The Institutional Review Board (IRB) will review the compliance of assurance and any part of a research project that meets the federal definitions of human subject research and/or clinical investigation.

Principal investigators (PIs) involved in stem cell research are responsible for:

The University of Iowa follows the procedures and policies as outlined in the Guidelines and expressed in the Guidelines for Human Embryonic Stem Cell Research and its subsequent amendments. These policies and procedures, and the review procedures of the hPSCC, are summarized in hPSCCs Policy and Standard Operating Procedures.

Registration may be required with the Institutional Animal Care and Use Committee (IACUC) if the project involves animal use and/or with the Institutional Biosafety Committee (IBC) if the project involves recombinant DNA.

The hPSCC will review for compliance all submitted hPSC Registration Documents and an approval/disapproval letter will be sent to the PI. The hPSCC will prohibit the initiation of experiments that are ineligible for NIH Funding. Prohibited experiments include:

The hPSCC will review all correspondence between the PI, IRB, IBC, IACUC and NIH, where applicable, in addition to the hPSC Registration Document.

International Society for Stem Cell Research International Society for Stem Cell Research Stem Cell Treatments National Institutes of Health Resource for Stem Cell Information Office of Animal Resources University of Iowa eIBC for Recombinant DNA Registration

View original post here:
Stem Cell Research | Environmental Health and Safety

References Adonai, N. Nguyen, K.N. Walsh, J. Iyer, M. Toyokuni, T. Phelps, M.E. McCarthy, T. McCarthy, D.W. Gambhir, S.S. (2002). Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA 99, 30303035. Abstract Article Alvarez-Maya, I. Navarro-Quiroga, I. Meraz-Rios, M.A. Aceves, J. Martinez-Fong, D. (2001). In vivo gene transfer to dopamine neurons of rat substantia nigra via the high-affinity neurotensin receptor. Mol Med 7, 186192. Abstract Anversa, P. Leri, A. Kajstura, J. (2006). Cardiac regeneration. J Am Coll Cardiol 47, 17691776. Abstract Article Arbab, A.S. Bashaw, L.A. Miller, B.R. Jordan, E.K. Bulte, J.W. Frank, J.A. (2003). Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 76, 11231130. Abstract Article Askenasy, N. Zorina, T. Farkas, D.L. Shalit, I. (2002). Transplanted hematopoietic cells seed in clusters in recipient bone marrow in vivo. Stem Cells 20, 301310. Abstract Article Baizabal, J.M. Furlan-Magaril, M. Santa-Olalla, J. Covarrubias, L. (2003). Neural stem cells in development and regenerative medicine. Arch Med Res 34, 572588. Abstract Article Bengel, F.M. Anton, M. Richter, T. Simoes, M.V. Haubner, R. Henke, J. Erhardt, W. Reder, S. Lehner, T. Brandau, W. et al. (2003). Noninvasive imaging of transgene expression by use of positron emission tomography in a pig model of myocardial gene transfer. Circulation 108, 21272133. Abstract Article Bengel, F.M. Schachinger, V. Dimmeler, S. (2005). Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging 32(Suppl 2), S404416. Article Bindslev, L. Haack-Sorensen, M. Bisgaard, K. Kragh, L. Mortensen, S. Hesse, B. Kjaer, A. Kastrup, J. (2006). Labelling of human mesenchymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation. Eur J Nucl Med Mol Imaging 33, 11711177. Abstract Article

Bloor, C.M. White, F.C. Roth, D.M. (1992). The pig as a model of myocardial ischemia and gradual coronary artery occlusion. In Swine as models in biomedical research. Swindle, M. M. Moody, D. C. Phillips, L. D. Ames, Iowa: Iowa State University Press; , 163175.

Kutschka, I. Chen, I.Y. Kofidis, T. Arai, T. von Degenfeld, G. Sheikh, A.Y. Hendry, S.L. Pearl, J. Hoyt, G. Sista, R. et al. (2006). Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation 114, I167173.

Kutschka, I. Kofidis, T. Chen, I.Y. von Degenfeld, G. Zwierzchoniewska, M. Hoyt, G. Arai, T. Lebl, D. R. Hendry, S. L. Sheikh, A. Y. et al. (2006). Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Circulation 114, I174180.

Li, Z. Wu, J.C. Sheikh, A.Y. Kraft, D. Cao, F. Xie, X. Patel, M. Gambhir, S.S. Robbins, R.C. Cooke, J.P. Wu, J.C. (2007). Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation 116, I4654.

Wang, F. Dennis, J. E. Awadallah, A. Solchaga, L. A. Molter, J. Kuang, Y. Salem, N. Lin, Y. Tian, H. Kolthammer, J. A. et al. (2008). Transcriptional Profiling of Human Mesenchymal Stem Cells Transduced with Reporter Genes for Imaging. Physiol Genomics.

Continue reading here:
Molecular imaging of stem cells | StemBook